1/13
02:19 pm
igms
IGM Biosciences, Inc. (NASDAQ: IGMS) was upgraded by analysts at JPMorgan Chase & Co. from an "underweight" rating to a "neutral" rating.
Low
Report
IGM Biosciences, Inc. (NASDAQ: IGMS) was upgraded by analysts at JPMorgan Chase & Co. from an "underweight" rating to a "neutral" rating.
1/13
01:50 pm
igms
Rating for IGMS
Medium
Report
Rating for IGMS
1/10
09:11 pm
igms
IGM Biosciences upgraded to Neutral from Underweight at JPMorgan
High
Report
IGM Biosciences upgraded to Neutral from Underweight at JPMorgan
1/10
12:48 pm
igms
Rating for IGMS
Medium
Report
Rating for IGMS
1/10
12:48 pm
igms
Rating for IGMS
Medium
Report
Rating for IGMS
1/10
12:06 pm
igms
IGM Biosciences, Inc. (NASDAQ: IGMS) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $3.00 price target on the stock, down previously from $22.00.
Medium
Report
IGM Biosciences, Inc. (NASDAQ: IGMS) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $3.00 price target on the stock, down previously from $22.00.
1/10
12:06 pm
igms
IGM Biosciences, Inc. (NASDAQ: IGMS) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $3.00 price target on the stock, down previously from $22.00.
Medium
Report
IGM Biosciences, Inc. (NASDAQ: IGMS) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $3.00 price target on the stock, down previously from $22.00.
1/10
11:54 am
igms
Rating for IGMS
Medium
Report
Rating for IGMS
1/10
11:36 am
igms
Rating for IGMS
Medium
Report
Rating for IGMS
1/10
11:36 am
igms
Rating for IGMS
Medium
Report
Rating for IGMS
1/10
10:51 am
igms
IGM Biosciences downgraded to Hold from Buy at Jefferies
Medium
Report
IGM Biosciences downgraded to Hold from Buy at Jefferies
1/10
10:51 am
igms
IGM Biosciences downgraded to Hold from Buy at Jefferies
Medium
Report
IGM Biosciences downgraded to Hold from Buy at Jefferies
1/10
08:30 am
igms
IGM Biosciences, Inc. (NASDAQ: IGMS) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.
Low
Report
IGM Biosciences, Inc. (NASDAQ: IGMS) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.
1/10
08:30 am
igms
IGM Biosciences, Inc. (NASDAQ: IGMS) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.
Low
Report
IGM Biosciences, Inc. (NASDAQ: IGMS) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.
1/10
08:30 am
igms
IGM Biosciences, Inc. (NASDAQ: IGMS) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating. They now have a $1.50 price target on the stock, down previously from $20.00.
Low
Report
IGM Biosciences, Inc. (NASDAQ: IGMS) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating. They now have a $1.50 price target on the stock, down previously from $20.00.
1/10
08:30 am
igms
IGM Biosciences, Inc. (NASDAQ: IGMS) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating. They now have a $1.50 price target on the stock, down previously from $20.00.
Low
Report
IGM Biosciences, Inc. (NASDAQ: IGMS) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating. They now have a $1.50 price target on the stock, down previously from $20.00.
1/10
08:30 am
igms
IGM Biosciences, Inc. (NASDAQ: IGMS) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $2.50 price target on the stock, down previously from $27.00.
Low
Report
IGM Biosciences, Inc. (NASDAQ: IGMS) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $2.50 price target on the stock, down previously from $27.00.
1/10
08:30 am
igms
IGM Biosciences, Inc. (NASDAQ: IGMS) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $2.50 price target on the stock, down previously from $27.00.
Low
Report
IGM Biosciences, Inc. (NASDAQ: IGMS) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $2.50 price target on the stock, down previously from $27.00.
1/10
08:30 am
igms
IGM Biosciences, Inc. (NASDAQ: IGMS) was downgraded by analysts at Morgan Stanley from an "equal weight" rating to an "underweight" rating. They now have a $2.00 price target on the stock, down previously from $12.00.
Low
Report
IGM Biosciences, Inc. (NASDAQ: IGMS) was downgraded by analysts at Morgan Stanley from an "equal weight" rating to an "underweight" rating. They now have a $2.00 price target on the stock, down previously from $12.00.
1/10
08:30 am
igms
IGM Biosciences, Inc. (NASDAQ: IGMS) was downgraded by analysts at Morgan Stanley from an "equal weight" rating to an "underweight" rating. They now have a $2.00 price target on the stock, down previously from $12.00.
Low
Report
IGM Biosciences, Inc. (NASDAQ: IGMS) was downgraded by analysts at Morgan Stanley from an "equal weight" rating to an "underweight" rating. They now have a $2.00 price target on the stock, down previously from $12.00.
1/10
08:04 am
igms
IGM Biosciences, Inc. (NASDAQ: IGMS) had its "market perform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $2.00 price target on the stock, down previously from $21.00.
Low
Report
IGM Biosciences, Inc. (NASDAQ: IGMS) had its "market perform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $2.00 price target on the stock, down previously from $21.00.
1/10
06:05 am
igms
IGM Biosciences downgraded to Neutral from Buy at Guggenheim
Medium
Report
IGM Biosciences downgraded to Neutral from Buy at Guggenheim
1/10
06:05 am
igms
IGM Biosciences downgraded to Neutral from Buy at Guggenheim
Medium
Report
IGM Biosciences downgraded to Neutral from Buy at Guggenheim
1/10
05:34 am
igms
IGM Biosciences downgraded to Sector Perform from Outperform at RBC Capital
Report
IGM Biosciences downgraded to Sector Perform from Outperform at RBC Capital
1/10
05:34 am
igms
IGM Biosciences downgraded to Sector Perform from Outperform at RBC Capital
Report
IGM Biosciences downgraded to Sector Perform from Outperform at RBC Capital